Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02451943 · ClinicalTrials.gov registry record · Phase 3
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 509
- Enrollment target
NCT02451943 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 509 participants.
The verdict
NCT02451943, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 509 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
Interventions
- DRUG Placebo
- DRUG Doxorubicin
- DRUG Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2015-09-14 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02451943
The ClinicalTrials.gov registry entry for NCT02451943 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02451943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02451943 about?
NCT02451943 is a clinical study titled "A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma". The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
What is the current status of trial NCT02451943?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 509 participants. The study started on 2015-09-14. Estimated completion is 2024-06-27.
What interventions are being tested in trial NCT02451943?
The interventions under investigation include: Placebo (DRUG), Doxorubicin (DRUG), Olaratumab (DRUG).
Who is sponsoring clinical trial NCT02451943?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.